EP0089426A1 - 2-Amino-6-biphenylacetic acids - Google Patents

2-Amino-6-biphenylacetic acids Download PDF

Info

Publication number
EP0089426A1
EP0089426A1 EP82301438A EP82301438A EP0089426A1 EP 0089426 A1 EP0089426 A1 EP 0089426A1 EP 82301438 A EP82301438 A EP 82301438A EP 82301438 A EP82301438 A EP 82301438A EP 0089426 A1 EP0089426 A1 EP 0089426A1
Authority
EP
European Patent Office
Prior art keywords
amino
compound
methylthio
indolin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP82301438A
Other languages
German (de)
French (fr)
Other versions
EP0089426B1 (en
Inventor
David Allan Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AH Robins Co Inc
Original Assignee
AH Robins Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AH Robins Co Inc filed Critical AH Robins Co Inc
Priority to AT82301438T priority Critical patent/ATE20343T1/en
Priority to DE8282301438T priority patent/DE3271619D1/en
Publication of EP0089426A1 publication Critical patent/EP0089426A1/en
Application granted granted Critical
Publication of EP0089426B1 publication Critical patent/EP0089426B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to ravel biphenylacetic acids and is more particularly concerned with certain 2-amino-6-biphenylacetic acids, esters, and metal salts, compositions thereof, methods for the production thereof and use of the same.
  • a therapeutic composition suitable for providing muscle relaxation comprising (a) an effective amount of a compound having the structural formula of Formula I and (b) a pharmaceutically acceptable carrier therefor.
  • the present invention also extends to compounds of Formula I for use in providing muscle relaxation in a living animal body with a minimum of undesirable side effects by internally administering to the said living animal body an effective amount of the said compound.
  • a therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of a compound having the structural formula of Formula I, and (b) a pharmaceutically acceptable carrier therefor.
  • the present invention also extends to compounds of Formula I for use in alleviating inflammation in a li 7 ing animal body with a minimum of undesirable side effects by internally administering to the said living animal body an effective amount of the said compound.
  • novel compounds of this invention are useful as muscle relaxant and anti-inflammatory agents.
  • the compounds may be administered alone or with suitable pharmaceutical carriers to warm blooded animals, mammals such as felines, canines and humans and can be in solid or liquid form as, for example, tablets, capsules, powders, solutions, suspensions or emulsions.
  • the compounds can be administered orally, parenterally, subcutaneously or intramuscularly.
  • the unit dosage form can contain from about 1 to about 100 milligrams of a compound of this invention and can be administered in multiples thereof up to a daily dosage level of about 500 milligrams.
  • the solid unit dosage form can be a gelatin capsule containing a compound of this invention and a pharmaceutically acceptable filler or carrier such as sucrose, lactose or corn starch. Tablets containing the compounds represent another embodiment of this invention and may be prepared using conventional tableting materials.
  • novel concept of the present invention resides in the provision of therapeutically active 6-biphenylacetic acids, esters and metal salts which have a primary amino group ortho to the acetic acid group.
  • Therapeutically active compounds possessing such an arrangement have been heretofore unknown prior to the present invention.
  • the anti-inflammatory utility of the compounds of this invention was determined using a modification of the Evans Blue-Carrageenan Pleural Effusion Assay of Sancilio, L.F., J. Pharmacol, Exp. Ther. 168, 199-204 (1969).
  • the muscle relaxant utility of the compounds of the present invention was determined using the loss of righting test as set forth by A.P.Roszkowski, J. Pharmacol. and Expt. Therapeutics, Vol 192, page 75 (1960).
  • lower alkvl as used herein means straight and branched chain radicals of un to six carbon atoms inclusive, preferably no more than four carbon atoms, and is exemplified by such groups as methyl, ethyl, propyl, isopropyl, butyl, sec. butyl, tertiary butyl, amyl, isoamyl and hexyl.
  • lower alkoxy has the formula -0-lower alkyl.
  • R 1 or R 2 can be the same or different radicals.
  • Illustrative of pharmaceutically acceptable salts are the scdium, potassium, calcium, magnesium, zinc, and copper salts and the hydrates thereof.
  • the compounds of Formula I wherein R represents hydrogen may be prepared by hydrolysis of 4- p henylindolin 2-ones (II) in aqueous basic solution followed by neutralization of the basic reaction mixture with a suitable organic acid such as acetic acid or a dilute acid as indicated by the following reaction scheme: Formula II wherein R 1 and R 2 are as defined hereinabove.
  • the hydrolysis of a 4-phenylindolin-2-one (II) may be carried out in a dilute aqueous base as, for example, a 3N sodium hydroxide solution, for a period of from about 1.0 to about 60 hours, usually until the indolin-2-one has dissolved.
  • the hydrolysis may be carried out in an inert atmosphere using nitrogen.
  • the hydrolysis mixture may be filtered to remove base- insoluble materials and the pH of the basic solution is adjusted to a p H of from 6-7 by the addition of a weak organic acid such as glacial acetic acid or a dilute mineral acid such as hydrochloric acid.
  • the free acids can contain water of crystallization. Therefore the free acids containing various degrees of hydration are included within the scope of the present invention.
  • the lower alkyl esters of Formula I are preferably prepared from the acids which are converted to an alkali tetal salt, preferably the sodium or potassium salt which is isolated, dried, and then reacted in a suitable solvent as for example, dimethyl formamide, with an alkyl halide, preferably an alkyl iodide, to furnish the desired ester.
  • an alkali tetal salt preferably the sodium or potassium salt which is isolated, dried, and then reacted in a suitable solvent as for example, dimethyl formamide, with an alkyl halide, preferably an alkyl iodide, to furnish the desired ester.
  • the 4-phenylindolin-2-ones (II) may be prepared from appropriately substituted biphenylamines (V) by the following reaction sequence, wherein R 1 and R have the values hereinabove defined except additionally R 1 and R 2 may be nitro in Formulas III, IV and V, and R represents a lower alkyl group, preferably an ethyl group.
  • R 1 and R have the values hereinabove defined except additionally R 1 and R 2 may be nitro in Formulas III, IV and V, and R represents a lower alkyl group, preferably an ethyl group.
  • the reaction conditions employed are more fully set forth hereinafter in the specific preparations which follow.
  • Compounds of Formula II wherein R1 or R 2 represent an-NH 2 group may be prepared from the corresponding biphenyl amine wherein R 1 or R 2 represent an -N0 2 group, the resulting -N0 2 radical in Formula III being reduced by RaNi (Raney Nickel) or Sn/HCl at the same time as the methylthio group is removed. Additional reducing agent may be required and in the instance of tin, three additional moles per mole of-N0 2 are required as well as sufficient HC1 to maintain acid conditions.
  • m-Biphenylamine hydrochloride (35.3g, 0.172 mole) was partitioned between 300 ml of methylene chloride and 200 ml of 5% sodium hydroxide solution. The layers were separated and the methylene chloride layer was dried (sodium sulphate) and its volume adjusted to 400 ml with additional methylene chloride. The solution was cooled to -65 0 C and 23.0g(0.172 mole) of ethyl 2-methylthioacetate were added. Immediately, 18.9g (0.175 mole) of t-butylhypochlorite were added dropwise.
  • the 4-phenyl isomer was separated from the 6-phenyl isomer by fractional crystallization from benzene.
  • Three recrystallizations of the yellow solid from benzene gave 8.5g (19%) of 3-methylthio-4-phenylindolin-2-one as a white solid, m.p. 182-5 0 C.
  • 3-methylthio-6-methyl-4-phenylindolin-2-one was replaced by equal molar amounts of the following methylthioindolin-2-ones: 3-methylthio-7-methyl-4-phenylindolin-2-one, 3-methylthio-6-methyl-4-phenylindolin-2-one, 3-methylthio-4-(2-methoxyphenyl)indolin-2-one, 3-methylthio-4-(2,5-dimethoxyphenyl)indolin-2-one, 3-methylthio-4-(3-chlorophenyl)indolin-2-one, 3-methylthio-4-(3,5-dibromophenyl)indolin-2-one, 3-methylthio-7-chloro-4-phenylindolin-2-one, 3-methylthio-5,7-dichloro-4-phenylindolin-2-one, 3-methylthio-4-(2-methylphenyl)indolin-2-one, and 3-methyl
  • compositions containing the compounds of the present invention as active ingredients.
  • Effective quantities of any of the foregoing pharmacologically active compounds may be administered to a living animal body in any one of various ways. For example, they may be orally administered in the form of sterile solutions.
  • the active ingredient is incorporated in a suitable carrier such as a pharmaceutical carrier.
  • suitable pharmaceutical carriers which are useful in formulating the compositions of this invention include starch, gelatin, glucose, magnesium carbonate, lactose, and malt.
  • suitable liquid pharmaceutical carriers include ethyl alcohol, propylene glycol, glycerine, and glucose syrup.
  • the pharmacologically active compounds of the present invention may be advantageously employed in a unit dosage of from about 1 to about 100 milligrams.
  • the unit dosage may be given a suitable number of times daily so that the daily dosage may vary from 1 to 500 milligrams. Five to 50 milligrams appears to be an optimum unit dose.
  • the active ingredient constitute an effective amount; i.e. such that a suitable effective dosage will be obtained consistent with the dosage form employed.
  • a suitable effective dosage will be obtained consistent with the dosage form employed.
  • the exact individual dosages as well as daily dosages will, of course, be determined according to standard medical principles under the direction of a physician or veterinarian.
  • the active agents of the present invention may be combined with the pharmacologically active agents, or with buffers, antacids or the like for administration.
  • the proportion of the active agent in the compositions may be varied widely.
  • compositions formed in accordance with this invention are examples of compositions formed in accordance with this invention.
  • Capsules of 5 mg, (Example llA), 25 mg (Example 11B), and 50 mg (Example 11C) of active ingredient per capsule were prepared. With the higher amounts of active ingredient, adjustment may be made in the amount of lactose.
  • Additional cansule formulations preferably contain a higher dosage of active ingredient and are as follows:-
  • the selected active ingredient was uniformly blended with the lactose, starch, and magnesium stearate and the blend encapsulated.
  • a typical formulation for a tablet containing 5.0 mg of active ingredient per tablet is as follows.
  • the formulation may be used for other strengths of active ingredient by adjusting the weight of the dicalcium phosphate.
  • the tablets were formed by uniformly blending ingredients 1, 2, 4 and 5.
  • Ingredient 3 was prepared as a 10 percent paste in water.
  • the blend was granulated with starch paste and the resulting wet mass passed through an eight mesh screen (U.S. Sieve size), having openings of 2.4 mms.
  • the wet granulations was dried and sized through a twelve mesh screen (U.S. Sieve size) having openings of 1.7 mms.
  • the dried granules were blended with the calcium stearate and pressed.
  • the solution was prepared, clarified by filtration and placed into vials.
  • the vials were sealed and heated in an autoclave.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel 2-amino-6-biphenylacetic acids, esters, and metal salts are provided of the formula
Figure imga0001
wherein R represents a hydrogen atom or a lower alkyl group or sodium or potassium atom, R1 represents a fluorine, chlorine or bromine atom or a lower-alkyl or amino group; R2 represents a lower-alkyl, lower alkoxy, amino or trifluoromethyl group or a fluorine, chlorine or bromine atom; n is 0-3 and m is 0-2, or the pharmaceutically acceptable salts thereof or hydrates thereof. The compounds exhibit muscle relaxant activity, and are also useful as anti-inflammatory agents.

Description

    TECHNICAL FIELD
  • The present invention relates to ravel biphenylacetic acids and is more particularly concerned with certain 2-amino-6-biphenylacetic acids, esters, and metal salts, compositions thereof, methods for the production thereof and use of the same.
  • BACKGROUND ART
  • Various biphenylacetic acids have been demonstrated to possess anti-inflammatory activity as disclosed in U.S. Patents 3,784,704 and 3,966,978. Biphenylacetic acids and esters having an amino substituent in the phenyl ring to which is attached the acetic acid moiety are disclosed in French Patent M 5,737. German Offenlegungs- schrift 2,355,084 discloses methyl 3-amino-4-biphenylace- tate as an intermediate in the preparation of phenanth- ridones.
  • DISCLOSURE OF THE INVENTION
  • According to one aspect of the present invention there is provided a compound having the structural formula:
    Figure imgb0001
    wherein:
    • R represents a hydrogen atom or a lower alkyl group,
    • R1 represents fluorine, chlorine, or bromine atom or a lower alkyl group or an amino group;
    • R2 represents a lower alkyl, lower alkoxy, amino, or trifluoromethyl group or a fluorine, chlorine or brcmine atom;
    • n is O-3 and m is 0-3,

    and the pharmaceutically acceptable salts thereof.
  • In another aspect of the present invention there is provided a therapeutic composition suitable for providing muscle relaxation comprising (a) an effective amount of a compound having the structural formula of Formula I and (b) a pharmaceutically acceptable carrier therefor.
  • The present invention also extends to compounds of Formula I for use in providing muscle relaxation in a living animal body with a minimum of undesirable side effects by internally administering to the said living animal body an effective amount of the said compound.
  • In still yet another aspect of the present invention there is provided a therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of a compound having the structural formula of Formula I, and (b) a pharmaceutically acceptable carrier therefor.
  • The present invention also extends to compounds of Formula I for use in alleviating inflammation in a li7ing animal body with a minimum of undesirable side effects by internally administering to the said living animal body an effective amount of the said compound.
  • The novel compounds of this invention are useful as muscle relaxant and anti-inflammatory agents. The compounds may be administered alone or with suitable pharmaceutical carriers to warm blooded animals, mammals such as felines, canines and humans and can be in solid or liquid form as, for example, tablets, capsules, powders, solutions, suspensions or emulsions.
  • The compounds can be administered orally, parenterally, subcutaneously or intramuscularly. The unit dosage form can contain from about 1 to about 100 milligrams of a compound of this invention and can be administered in multiples thereof up to a daily dosage level of about 500 milligrams.
  • The solid unit dosage form can be a gelatin capsule containing a compound of this invention and a pharmaceutically acceptable filler or carrier such as sucrose, lactose or corn starch. Tablets containing the compounds represent another embodiment of this invention and may be prepared using conventional tableting materials.
  • The novel concept of the present invention resides in the provision of therapeutically active 6-biphenylacetic acids, esters and metal salts which have a primary amino group ortho to the acetic acid group. Therapeutically active compounds possessing such an arrangement have been heretofore unknown prior to the present invention.
  • The anti-inflammatory utility of the compounds of this invention was determined using a modification of the Evans Blue-Carrageenan Pleural Effusion Assay of Sancilio, L.F., J. Pharmacol, Exp. Ther. 168, 199-204 (1969).
  • The muscle relaxant utility of the compounds of the present invention was determined using the loss of righting test as set forth by A.P.Roszkowski, J. Pharmacol. and Expt. Therapeutics, Vol 192, page 75 (1960).
  • It has been surprisingly and unexpectedly found that the 2-amino-6-biphenylacetic acids of the present invention exhibit significant muscle relaxant activity, while 2-aminobiphenylacetic acids having the phenyl substituent in the 3 and 5 positions exhibit no such activity. The surprising muscle relaxant properties of the 2-amino-6-biphenylacetic acids is clearly shown in the following Table.
    Figure imgb0002
  • In the definition of symbols in the formulae hereof and where they appear elsewhere throughout this specification, the terms have the following significance.
  • The term "lower alkvl" as used herein means straight and branched chain radicals of un to six carbon atoms inclusive, preferably no more than four carbon atoms, and is exemplified by such groups as methyl, ethyl, propyl, isopropyl, butyl, sec. butyl, tertiary butyl, amyl, isoamyl and hexyl. The term "lower alkoxy" has the formula -0-lower alkyl.
  • When m = 2 or n = 2 or 3, R1 or R2 can be the same or different radicals.
  • Illustrative of pharmaceutically acceptable salts are the scdium, potassium, calcium, magnesium, zinc, and copper salts and the hydrates thereof.
  • The compounds of Formula I wherein R represents hydrogen may be prepared by hydrolysis of 4-phenylindolin 2-ones (II) in aqueous basic solution followed by neutralization of the basic reaction mixture with a suitable organic acid such as acetic acid or a dilute acid as indicated by the following reaction scheme:
    Figure imgb0003
    Formula II wherein R1 and R2 are as defined hereinabove.
  • The hydrolysis of a 4-phenylindolin-2-one (II) may be carried out in a dilute aqueous base as, for example, a 3N sodium hydroxide solution, for a period of from about 1.0 to about 60 hours, usually until the indolin-2-one has dissolved. The hydrolysis may be carried out in an inert atmosphere using nitrogen. The hydrolysis mixture may be filtered to remove base- insoluble materials and the pH of the basic solution is adjusted to a pH of from 6-7 by the addition of a weak organic acid such as glacial acetic acid or a dilute mineral acid such as hydrochloric acid.
  • The free acids can contain water of crystallization. Therefore the free acids containing various degrees of hydration are included within the scope of the present invention.
  • The lower alkyl esters of Formula I are preferably prepared from the acids which are converted to an alkali tetal salt, preferably the sodium or potassium salt which is isolated, dried, and then reacted in a suitable solvent as for example, dimethyl formamide, with an alkyl halide, preferably an alkyl iodide, to furnish the desired ester.
  • The 4-phenylindolin-2-ones (II) may be prepared from appropriately substituted biphenylamines (V) by the following reaction sequence, wherein R1 and R have the values hereinabove defined except additionally R1 and R2 may be nitro in Formulas III, IV and V, and R represents a lower alkyl group, preferably an ethyl group. The reaction conditions employed are more fully set forth hereinafter in the specific preparations which follow.
    Figure imgb0004
  • Compounds of Formula II wherein R1 or R 2 represent an-NH2 group may be prepared from the corresponding biphenyl amine wherein R1 or R2 represent an -N02 group, the resulting -N02 radical in Formula III being reduced by RaNi (Raney Nickel) or Sn/HCl at the same time as the methylthio group is removed. Additional reducing agent may be required and in the instance of tin, three additional moles per mole of-N02 are required as well as sufficient HC1 to maintain acid conditions.
  • BEST MODE OF CARRYING OUT THE INVENTION
  • The invention may be put into practice in various ways and a number of specific embodiments will be described to illustrate the invention with reference to the accompanying examples which are preceeded by preparations which describe the preparation of starting materials and intermediates for use in the examples.
  • Preparation 1 3-Methylthio-4-phenylindolin-2-one
  • m-Biphenylamine hydrochloride (35.3g, 0.172 mole) was partitioned between 300 ml of methylene chloride and 200 ml of 5% sodium hydroxide solution. The layers were separated and the methylene chloride layer was dried (sodium sulphate) and its volume adjusted to 400 ml with additional methylene chloride. The solution was cooled to -650C and 23.0g(0.172 mole) of ethyl 2-methylthioacetate were added. Immediately, 18.9g (0.175 mole) of t-butylhypochlorite were added dropwise. After the addition was completed, the mixture was stirred at -65 C for 1.5 hours, treated with 17.2g(0.125 mole) of triethylamine and allowed to warm up to ambient temperature. The methylene chloride solution was washed twice with two 100 ml portions of water, concentrated, and the residue dissolved in 200 ml of methanol. This solution was heated to reflux, treated with 40 ml of 3N hydrochloric acid and the mixture heated at reflux overnight. The dark solution was concentrated to approximately 100 ml, when a solid began to precipitate. The mixture was cooled, the solid collected by filtration, washed with a small volume of cold methanol and dried to give 22.8g(52%) of yellow material. A nuclear magnetic resonance (NMR) analysis of the material indicated that the solid was a mixture of the 4-phenyl isomer and the 6-phenyl isomer in a ratic of 2:1. The 4-phenyl isomer was separated from the 6-phenyl isomer by fractional crystallization from benzene. Three recrystallizations of the yellow solid from benzene gave 8.5g (19%) of 3-methylthio-4-phenylindolin-2-one as a white solid, m.p. 182-50C.
  • Analysis: Calculated for C15H13NOS: C,70.56; H,5.13; N,5.49 Found : C,70.26, H,5.16; N,5.14
  • Preparation 2 4-Phenylindolin-2-one
  • A stirred solution of 3.5g (0.014 mole) of 4-phenyl-3-methylthioindolin-2-one in 75 ml of tetrahydrofuran was treated portionwise with 20g of a commercial Raney nickel/water suspension. The mixture was filtered through Celite (Registered Trade Marx) and the filtrate concentrated to give a yellow solid. This solid was recrystallized from benzene to yield 1.6g (57%) of product as an off-white solid. An analytical sample was prepared from isopropanol; m.p. 192-194°C.
  • Analysis: Calculated for C14H11NO: C,80.36; H,5.30; N,6.69 Found : C,80.52; H,5.41; N,6.72
  • Preparation 3 3-Methylthio-7-methyl-4-phenylindolin-2-one
  • A solution of 30.6g (0.13 mole) of 3-amino-4-methylbiphenyl in 400 ml of methylene chloride was cooled to -650C and treated witn 17.Og (0.13 mole) of ethyl 2-methylthioacetate and then 14.2g(0.132 mole) of t-butylhypochlorite while maintaining the temperature below -60°C. Tne reaction mixture was stirred at -65°C for 1.5 hours, treated with 13.3 (0.132 mole) of triethyl amine and allowea to warm up to ambient temperature. The solution was washed twice with water and concentrated. The residue was dissolved in 200 ml of methanol, 40 ml of 3N hydrochloric acid were added, and the mixture refluxed overnight. The solution was concentrated until a solid began to precipitate. The mixture was cooled, and the solid collected by filtration.
  • Preparations 4A to 4I
  • When in the procedure of Preparation 3 and in the manner of the preceding discussion, 3-amino-4-methylbiphenyl was replaced by equal molar amounts of the following:
    • 3-amino-5-methylbiphenyl,
    • 3-amino-2'-methoxybiphenyl,
    • 3-amino-2',5'dimethoxybiphenyl,
    • 3-amino-3'-chlorobiphenyl,
    • 3-amino-3',5'-dibromobiphenyl,
    • 3-amino-4-chlorobiphenyl,
    • 3-amino-4,6-dichlorobiphenyl,
    • 3-amino-6-methyl-2'-methylbiphenyl,
    • 3-amino-2',4-dichlorobiphenyl,

    there were obtained
    • 3-methylthio-6-methyl-4-phenylindolin-2-one and 3-methylthio-4-methyl-6-phenylindolin-2-one, (4A)
    • 3-methylthio-4-(2-methoxyphenyl)indolin-2-one and 3-methylthio-6-(2-methoxyphenyl)indolin-2-one, (4B)
    • 3-methylthio-4-(2,5-dimethoxyphenyl)indolin-2-one and 3-methylthio-6-(2,5-dimethoxyphenyl)indolin-2-one, (4C)
    • 3-methylthio-4-(3-chlorophenyl)indolin-2-one and 3-methylthio-6-(3-chlorophenyl)indolin-2-one, (4D)
    • 3-methylthio-4-(3,5-dibromophenyl)indolin-2-one and 3-methylthio-6-(3,5-dibromophenyl)indolin-2-one, (4E) 3-methylthio-7-chloro-4-phenylindclin-2-one, (4F) 3-methylthio-5, 7-dichloro-4-phenylindolin-2-one,(4G) 3-methylthio-5-methyl-4-(2-methylmenyl)indoline-2-one(4H) a 3-methylthio-7-chloro-4-(2-chlorochenyl)indolin-2-one. (4J).
  • Preparation 5
  • 6-Methyl-4-phenylindolin-2-one
  • To a slurry of 11.89(0.044 mole) of 3-methylthio-6-methyl-4-phenylindoline-2-one in 500 ml of tetrahydrofuran were added 100g of a commercial Ranev nickel/water preparation portionwise over a two-hour period. The mixture was filtered through Celite (Regist- ered Trade Mark) and the filtrate concentrated. A small amount of methylene chloride was added to the residue and the resulting solid was collected by filtration.
  • Preparations 6A to 6J
  • When in the procedure of Preparation 5 and in the manner of the preceding dicussion, 3-methylthio-6-methyl-4-phenylindolin-2-one was replaced by equal molar amounts of the following methylthioindolin-2-ones: 3-methylthio-7-methyl-4-phenylindolin-2-one, 3-methylthio-6-methyl-4-phenylindolin-2-one, 3-methylthio-4-(2-methoxyphenyl)indolin-2-one, 3-methylthio-4-(2,5-dimethoxyphenyl)indolin-2-one, 3-methylthio-4-(3-chlorophenyl)indolin-2-one, 3-methylthio-4-(3,5-dibromophenyl)indolin-2-one, 3-methylthio-7-chloro-4-phenylindolin-2-one, 3-methylthio-5,7-dichloro-4-phenylindolin-2-one, 3-methylthio-4-(2-methylphenyl)indolin-2-one, and 3-methylthio-7-chloro-4-(2-chlorophenyl)indolin-2-one, there were obtained
    • 7-methyl-4-phenylindolin-2-one, (6A)
    • 6-methyl-4-phenylindolin-2-one, (6B)
    • 4-(2-methoxyphenyl)indolin-2-one, (6C)
    • 4-(2,5-dimethoxyphenyl)indolin-2-one, (6D)
    • 4-(3-chlorophenyl)indolin-2-one, (6E)
    • 4-(3,5-dibromophenyl)indolin-2-one, (6F)
    • 7-chloro-4-phenylindolin-2-one, (6G)
    • 5,7-dichloro-4-phenylindolin-2-one, (6H)
    • 5-methyl-4-(2-methylpheriyl)indolin-2-one, (6I) and
    • 7-chloro-4-(2-chlorophenyl)indolin-2-one. (6J)
    Preparations 7A to 7C
  • When in the procedure of Preparation 3 and in the manner of the preceding discussion, 3-amino-4-methylbiphenyl was replaced by equal molar amounts of the following nitro derivatives:
    • 3-amino-3'-nitrobiphenyl,
    • 3-amino-2'-nitrobiphenyl,
    • 3-amino-4,6-dinitrobiphenyl,
    • there were obtained.
    • 3-methylthio-4-13-nitrophenyl)indolin-2-one, and 3-methylthio-6-(3-nitrophenyl)indolin-2-one, (7A)
    • 3-methylthio-6-(3-nitrophenyl)indolin-2-one, and 3-methylthio-6-(2-nitrophenyl)indolin-2-one, (7B) and
    • 3-methylthio-4-phenyl-5,7-dinitroindolin-2-one (7C)
    Preparation 8 4-Phenyl-5,7-diaminoindolin-2-one
  • A mixture of 4.9g (0.014 mole) of 3-methylthio-4-phenyl-5,7-dinitroindolin-2-one (see Preparation 7C), 4.2g (0.035 mole) of tin powder, 10 ml of concentrated hydrochloric acid and 50 ml of ethanol were refluxed for 4 hours under nitrogen. The hot mixture was filtered and the filtrate concentrated to give a solid.
  • Preparations 9A and 9B
  • When in the procedure of Preparation 8 and in the manner of the preceding discussion, 3-methylthio-4-phenyl-5,7-dinitroindolin-2-one was replaced by equal molar amounts of the following nitro-methylthioindolins of Preparation 7:
    • 3-methylthio-4- (3-nitrophenyl)indolin-2-one, (see 7A)
    • 3-methylthio-4-(2-nitrophenyl)indolin-2-one, (see 7B)

    there were obtained
    • 4-(3-aminophenyl)indolin-2-one, (9A) and
    • 4-(2-aminophenyl)indolin-2-one (9B).
    Example 1 2-Amino-3-methyl-6-biphenvlacetic Acid Hydrate (1:4)
  • A mixture of 4.79g (0.0215 mole) of 7-methyl-4-phenylindolin-2-one (see Preparation 6A) and 60 ml of 3N sodium hydroxide was heated at reflux under nitrogen for 17 hours. The reaction mixture was cooled, filtered, and the filtrate diluted with 60 ml of water. The solution was cooled, made acidic with glacial acid and the resulting solid immediately collected by filtration, washed with cold water and dried under vacumm.
  • Example 2 2-Amino-6-biphenylacetic Acid
  • A mixture of 1.5g (0.007 mole) of 4-phenylindolin-2-one (see Preparation 2) and 20 ml of 3N sodium hydroxide was heated at reflux for 6 hours. The mixture was cooled and filtered. The filtrate was made acidic with glacial acetic acid, and the resulting solid collected by filtration, washed with water and dried to yield 0.5 g (32%) of product as a tan powder, m.p. 190-191°C (dec.).
  • Analysis: Calculated for C14H13NO2: C,73,99; H,5.77: N,6.16 Found : C,73.54; H,5.71; N,6.28
  • Example 3 Sodium 2-amino-6-biphenylacetate
  • A solution of 2.8g (0.0125 mole) of crude 2-amino-6-biphenylacetic acid in 40 ml of tetrahydrofuran was treated with 2 ml of 5% sodium hydroxide. The solution was concentrated and the residue subject to a benzene azetrope to eliminate water. The resulting tan solid was recrystallized three times from ethyl alcohol to give a pure sample of the sodium salt as a tan solid, m.p. 128-48°C. (dec.)
  • Analysis: Calculated for C14H12NaNO2: C,67.46; H,4.85; N,5.62 Found :C,67.25; H,4.96; N,5.65
  • Example 4
  • When in the procedure of Example 1 and in the manner of the preceding discussion, 7-methyl-4-phenylindolin-2- one was replaced by equal molar amounts of
    • 5-methyl-4-(2-methylphenyl)indolin-2-one (see 6I) there was obtained
    • 2-amino-5,2'-dimethyl-6-biphenylacetic acid.
    Examples 5A and 5B
  • When in the procedure of Example 1 and in the manner of the preceding discussion, 7-methyl-4-phenylindolin-2-one was replaced by equal molar amounts of
    • 4-(2-methoxyphenyl)indolin-2-one, (see 6C)
    • 4-(2,5-dimkthoxvphenyl)indolin-2-one (see 6D) there were obtained
    • 2-amino-2'-methoxy-6-biphenylacetic acid (Example 5A).
    • 2 amino-2',5-dimethoxv-6-biphenylacetic acid (Example 5B)
    Examples 6A and 6B
  • When in the manner of Example 1 and in the manner of the preceding discussion, 7-methyl-4-phenylindolin-2- one was replaced by equal molar amounts of 4-(3,5-dibromophenyl)indolin-2-one, (see 6F) 7-chloro-4-(2-chlorophenyl)indelin-2-one, (see 6J) there were obtained
    • 2-amino-3',5'-dibromo-6-biDhenylacetic acid, (Example 6A)
    • 2-amino-2',3-dichloro-6-biphenylacetic acid (Example 6B)
    Examples 7A and 7B
  • When in the procedure of Example 1, 2 moles of potassium hydroxide per mole of the indolin-2-one was substituted for the sodium hydroxide, ethanol was substituted for water and 7-methyl-4-phenylindolin-2-one was replaced by equal molar amounts of
    • 4-(3-aminophenyl)indolin-2-one, (see 9A)
    • 4-(2-aminophenyl)indolin-2-one (see 9B) there were obtained
    • 2,3'-diamino-6-biphenylacetic acid (Example 7A)
    • 2,2-diamino-6-biphenylacetic acid (Example 7B)
    Example 8
  • When in the procedure of Example 1, 2 moles of potassium hydroxide per mole of the phenylindolin-2-one was substituted for the sodium hydroxide, ethanol was substituted for water and 7-methyl-4-phenylindolin-2-one was replaced by equal molar amounts of
    • 4-phenyl-5,7-diaminoindolin-2-one (see 8) there was obtained
    • 2,3,5-triamino-6-biphenylacetic acid.
    Examples 9A to 9D
  • When in the procedure of Example 1 and in the manner of the preceding discussion, 7-methyl-4-phenylin- dolin-2-one was replaced by equal molar amounts of
    • 6-methyl-4-phenylindolin-2-one (see 6B)
    • 4-(3-chlorophenyl)indolin-2-one (see 6E)
    • 7-chloro-4-phenylindolin-2-one (see 6G)
    • 5,7-dichloro-4-phenylindolin-2-one, (see 6H) there were obtained
    • 2-amino-4-methyl-6-biphenylacetic acid (Example 9A)
    • 2-amino-3'-chloro-6-biphenylacetic acid (Example 9B)
    • 2-amino-3-chloro-6-biphenylacetic acid (Example 9C)
    • 2-amino-3,5-dichloro-6-biphenylacetic acid (Example 9D).
    Example 10 Ethyl 2-Amino-G-biphenylacetate
  • Sodium 2-amino-6-biphenylacetate was dissolved in dimethylformamide and the solution treated with ethylio- dide. The solution was stirred at room temperature for about 3 hours, the solution added to water and the mixture extracted several times with benzene. The combined benzene extracts were washed with dilute base and water, dried over sodium sulphate, concentrated under reduced pressure and crystallized to give ethyl 2-amino-6-biphenylacetate.
  • Formulation and Administration
  • The present invention also contemplates compositions containing the compounds of the present invention as active ingredients. Effective quantities of any of the foregoing pharmacologically active compounds may be administered to a living animal body in any one of various ways. For example, they may be orally administered in the form of sterile solutions. In forming the compositions of this invention, the active ingredient is incorporated in a suitable carrier such as a pharmaceutical carrier. Suitable pharmaceutical carriers which are useful in formulating the compositions of this invention include starch, gelatin, glucose, magnesium carbonate, lactose, and malt. Liquid compositions are also within the purview of this invention and suitable liquid pharmaceutical carriers include ethyl alcohol, propylene glycol, glycerine, and glucose syrup.
  • The pharmacologically active compounds of the present invention may be advantageously employed in a unit dosage of from about 1 to about 100 milligrams. The unit dosage may be given a suitable number of times daily so that the daily dosage may vary from 1 to 500 milligrams. Five to 50 milligrams appears to be an optimum unit dose.
  • It is only necessary that the active ingredient constitute an effective amount; i.e. such that a suitable effective dosage will be obtained consistent with the dosage form employed. The exact individual dosages as well as daily dosages will, of course, be determined according to standard medical principles under the direction of a physician or veterinarian.
  • The active agents of the present invention may be combined with the pharmacologically active agents, or with buffers, antacids or the like for administration. The proportion of the active agent in the compositions may be varied widely.
  • The following are examples of compositions formed in accordance with this invention.
  • Examples 11A to 11C
  • Capsules of 5 mg, (Example llA), 25 mg (Example 11B), and 50 mg (Example 11C) of active ingredient per capsule were prepared. With the higher amounts of active ingredient, adjustment may be made in the amount of lactose.
  • Example 11A
  • Figure imgb0005
  • Example 11B
  • Additional cansule formulations preferably contain a higher dosage of active ingredient and are as follows:-
    Figure imgb0006
  • In each case the selected active ingredient was uniformly blended with the lactose, starch, and magnesium stearate and the blend encapsulated.
  • Example 12
  • A typical formulation for a tablet containing 5.0 mg of active ingredient per tabletis as follows. The formulation may be used for other strengths of active ingredient by adjusting the weight of the dicalcium phosphate.
    Figure imgb0007
  • The tablets were formed by uniformly blending ingredients 1, 2, 4 and 5. Ingredient 3 was prepared as a 10 percent paste in water. The blend was granulated with starch paste and the resulting wet mass passed through an eight mesh screen (U.S. Sieve size), having openings of 2.4 mms. The wet granulations was dried and sized through a twelve mesh screen (U.S. Sieve size) having openings of 1.7 mms. The dried granules were blended with the calcium stearate and pressed.
  • Example 13
  • An injectable 2% sterile solution was made up as follows:-
    Figure imgb0008
  • The solution was prepared, clarified by filtration and placed into vials. The vials were sealed and heated in an autoclave.

Claims (10)

1. A compound having the structural formula:-
Figure imgb0009
wherein:
R represents a hydrogen atom or a lower alkyl group
R represents a fluorine, chlorine or bromine atom or a lower alkyl or amino group.
R2 represents a lower alkyl, lower alkoxy, amion or trifluoromethyl group or a fluorine, chlorine or bromine atom,
n is O-3 and m is 0-2, or a pharmaceutically acceptable salt thereof or a hydrate thereof.
2. 2-Amino-6-biphenylacetic acid or a pharmaceut- ically acceptable salt thereof.
3. A compound as claimed in claim 1 in which R represents a methyl group or an amino group or a chlorine atom, and m = 1, and n = 0.
4. A compound as claimed in claim 1 in which m = 0, R2 represents a methoxy group, an amino group, or a chlorine atom and n = 1.
5. A compound as claimed in claim 1 in which m = 2, R represents an amino group or a chlorine atom and n = 0.
6. A compound as claimed in claim 1 in which m = 0, R2 represents a methoxy group or a bormine atom and n = 2.
7. A compound as claimed in claim 5 or claim 6 in which the R substituents are the same or the R2 substituents are the same.
8. A muscle relaxation or inflammation alleviating composition comprising (a) as the active ingredient an effective amount of a compound as claimed in anyone of claims 1 to 7 and (b) a pharmaceutically acceptable carrier therefor.
9. A composition as claimed in claim 8 in which the effective amount ranges between 1 and 100 milligrams of the active ingredient.
10. A compound as claimed in anyone of claims 1 to 7 or a composition as claimed in claim 8 or claim 9 for use in muscle relaxation in a living animal body or for use in alleviating inflammation in a living animal body.
EP82301438A 1979-07-12 1982-03-19 2-amino-6-biphenylacetic acids Expired EP0089426B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT82301438T ATE20343T1 (en) 1982-03-19 1982-03-19 2-AMINO-6-BIPHENYLACETIC ACIDS.
DE8282301438T DE3271619D1 (en) 1982-03-19 1982-03-19 2-AMINO-6-BIPHENYLACETIC ACIDS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5711879A 1979-07-12 1979-07-12

Publications (2)

Publication Number Publication Date
EP0089426A1 true EP0089426A1 (en) 1983-09-28
EP0089426B1 EP0089426B1 (en) 1986-06-11

Family

ID=22008618

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82301438A Expired EP0089426B1 (en) 1979-07-12 1982-03-19 2-amino-6-biphenylacetic acids

Country Status (4)

Country Link
EP (1) EP0089426B1 (en)
JP (1) JPS58183653A (en)
AU (1) AU553122B2 (en)
CA (1) CA1173853A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558158A1 (en) * 1984-01-13 1985-07-19 Roussel Uclaf INDOLE ETHENYL PHENOL DERIVATIVES, THEIR SALTS, PROCESS FOR THE PREPARATION, APPLICATION AS MEDICAMENTS, COMPOSITIONS CONTAINING SAME AND INTERMEDIATES
US4791109A (en) * 1985-07-11 1988-12-13 Roussel Uclaf Novel indole carboxamides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518528A1 (en) * 1964-01-24 1969-02-27 Boots Pure Drug Co Ltd Therapeutic preparation with anti-inflammatory, antipyretic and analgesic effects
DE2355084A1 (en) * 1972-11-06 1974-05-16 Guidotti & C Spa Labor COMPOUNDS HAVING A GASTIC ACID SECRETION-INHIBITING EFFECT AND PROCESS FOR THEIR PRODUCTION
US4045576A (en) * 1975-08-13 1977-08-30 A. H. Robins Company, Incorporated Anti-inflammatory methods using 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof and the compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518528A1 (en) * 1964-01-24 1969-02-27 Boots Pure Drug Co Ltd Therapeutic preparation with anti-inflammatory, antipyretic and analgesic effects
DE2355084A1 (en) * 1972-11-06 1974-05-16 Guidotti & C Spa Labor COMPOUNDS HAVING A GASTIC ACID SECRETION-INHIBITING EFFECT AND PROCESS FOR THEIR PRODUCTION
US4045576A (en) * 1975-08-13 1977-08-30 A. H. Robins Company, Incorporated Anti-inflammatory methods using 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof and the compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558158A1 (en) * 1984-01-13 1985-07-19 Roussel Uclaf INDOLE ETHENYL PHENOL DERIVATIVES, THEIR SALTS, PROCESS FOR THE PREPARATION, APPLICATION AS MEDICAMENTS, COMPOSITIONS CONTAINING SAME AND INTERMEDIATES
EP0150139A2 (en) * 1984-01-13 1985-07-31 Roussel-Uclaf Indole-ethylphenol derivatives, their salts, process for their peparation, their uses as medicines and compositions containing them
EP0150139A3 (en) * 1984-01-13 1985-08-21 Roussel-Uclaf Indole-ethylphenol derivatives, their salts, process for their peparation, their uses as medicines and compositions containing them and intermediaries
US4791109A (en) * 1985-07-11 1988-12-13 Roussel Uclaf Novel indole carboxamides

Also Published As

Publication number Publication date
AU8180982A (en) 1983-09-29
EP0089426B1 (en) 1986-06-11
JPS58183653A (en) 1983-10-26
AU553122B2 (en) 1986-07-03
CA1173853A (en) 1984-09-04
JPH0249298B2 (en) 1990-10-29

Similar Documents

Publication Publication Date Title
US4670566A (en) 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4440785A (en) Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
CA1087205A (en) 2-amino-3-(5-and 6-)benzoylphenylacetic acids, esters and metal salts thereof
DE3033157A1 (en) 7-AMINO-1-CYCLOPROPYL-4-OXO-1,4-DIHYDRO-NAPHTHYRIDINE-3-CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THE ANTIBACTERIAL AGENTS CONTAINING THEM
JPH02117664A (en) 4-pyridone-3-carboxylic acid and its derivative
US4313949A (en) Method of producing an inhibitory effect on blood platelet aggregation
US4503073A (en) 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
US3637852A (en) 1-phenoxy-2-hydroxy-3-isopropylamino-propanes and salts thereof
CA1146964A (en) 3-benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
US3622675A (en) Anorexigenic composition and method
DE2461802A1 (en) PYRAZINE DERIVATIVES
JPH0153266B2 (en)
EP0089426B1 (en) 2-amino-6-biphenylacetic acids
US4333951A (en) 2-Amino-6-biphenylacetic acids
US3830817A (en) 1-aziridinylcarbonyl-quinoline-carboxylic acid derivatives
KR880002289B1 (en) 2-amino-2-(holobenzoyl)-methyl phenyl acetic acid and process for the preparation of their derivatives
JPH0141616B2 (en)
US5071849A (en) Dihydropyrimidothiazine derivatives
US3979468A (en) 4'-Chloro-4-ethynylbiphenyl and method of preparing same
CA1147746A (en) 2-amino-3-(alkylthiobenzoyl)phenylacetic acids
EP0058009A1 (en) Novel benzanilide derivatives and pharmaceutical compositions containing them
US3325360A (en) Pyrimidine-di-one pharmaceutical compositions having anti-inflammatory activity
EP0058534A2 (en) Hexahydro-1,2,4-triazine-3,5-dione derivatives and their use as feed additives
US3546245A (en) 2-(1-lower-alkyl-3-pyrrolidinyl)-1,3-propanediol dicarbamates
HU209245B (en) Process for producing new cimetidine derivatives, as well as new gastric acid secretion inhibiting and gastrocytoprotective pharmaceuitcal compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19840320

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: A.H. ROBINS COMPANY, INCORPORATED

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 20343

Country of ref document: AT

Date of ref document: 19860615

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3271619

Country of ref document: DE

Date of ref document: 19860717

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: AHP SUBSIDIARY (9) CORPORATION

Ref country code: CH

Ref legal event code: PFA

Free format text: A. H. ROBINS COMPANY, INCORPORATED (A DELAWARE CORPORATION)

ITPR It: changes in ownership of a european patent

Owner name: CAMBIO RAGIONE SOCIALE;A.H. ROBINS COMPANY, INCORP

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: AHP SUBSIDIARY (9) CORPORATION TE RICHMOND, VIRGIN

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: A.H. ROBINS COMPANY, INCORPORATED TE RICHMOND, VIR

EPTA Lu: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19950117

Year of fee payment: 14

EAL Se: european patent in force in sweden

Ref document number: 82301438.6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19950309

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19950313

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19950315

Year of fee payment: 14

Ref country code: CH

Payment date: 19950315

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19950322

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19950331

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19950401

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19950428

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960319

Ref country code: GB

Effective date: 19960319

Ref country code: AT

Effective date: 19960319

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19960331

Ref country code: CH

Effective date: 19960331

Ref country code: BE

Effective date: 19960331

BERE Be: lapsed

Owner name: A.H. ROBINS CY INC. (ETAT DE DELAWARE)

Effective date: 19960331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19961001

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19960319

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19961129

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19961001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19961203

EUG Se: european patent has lapsed

Ref document number: 82301438.6

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST